Which antibiotic for resistant Gram-positives, and why?

被引:18
作者
Bradley, John S. [1 ]
机构
[1] Univ Calif San Diego, Sch Med, Rady Childrens Hosp, San Diego, CA 92103 USA
关键词
Staphylococcus aureus; Methicillin-resistant; Enterococcus vancomycin-resistant; Antibiotic resistance; Linezolid; Daptomycin; Vancomycin; Ceftaroline; INTERMEDIATE STAPHYLOCOCCUS-AUREUS; INCLUDING VANCOMYCIN-INTERMEDIATE; MINIMUM INHIBITORY CONCENTRATION; ENTEROCOCCUS-FAECIUM BACTEREMIA; INFECTIOUS-DISEASES SOCIETY; METHICILLIN-RESISTANT; QUINUPRISTIN-DALFOPRISTIN; GLYCOPEPTIDE RESISTANCE; ANTIMICROBIAL THERAPY; LINEZOLID-RESISTANT;
D O I
10.1016/j.jinf.2013.09.016
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Increasing resistance in Gram-positive pathogens, particularly Staphylococcus aureus, and enterococcus, has become a major clinical problem, particularly in the hospital environment, causing significant morbidity and mortality in both healthy hosts and in those with underlying comorbidities. Increased resistance drives the use of empiric therapy with less well-studied and potentially more toxic agents. Resistance mechanisms for currently recommended agents are discussed, with options for therapy of resistant pathogens. For any new agent used, resistance is likely to develop, which underscores the concept that both antibiotics and antimicrobial resistance are ancient, and only by prudent use of antimicrobial agents and effective infection control measures when resistance arises, will effective agents be available to treat Gram-positive pathogens in the future. (C) 2013 Published by Elsevier Ltd on behalf of The British Infection Association.
引用
收藏
页码:S63 / S75
页数:13
相关论文
共 81 条
  • [1] Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes
    Aoki, H
    Ke, LZ
    Poppe, SM
    Poel, TJ
    Weaver, EA
    Gadwood, RC
    Thomas, RC
    Shinabarger, DL
    Ganoza, MC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1080 - 1085
  • [2] The rise of the Enterococcus: beyond vancomycin resistance
    Arias, Cesar A.
    Murray, Barbara E.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2012, 10 (04) : 266 - 278
  • [3] Glycopeptide resistance in enterococci
    Arthur, M
    Reynolds, P
    Courvalin, P
    [J]. TRENDS IN MICROBIOLOGY, 1996, 4 (10) : 401 - 407
  • [4] Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564
  • [5] Genomics and the ancient origins of the daptomycin biosynthetic gene cluster
    Baltz, Richard H.
    [J]. JOURNAL OF ANTIBIOTICS, 2010, 63 (08) : 506 - 511
  • [6] Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus
    Boucher, Helen W.
    Sakoulas, George
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 45 (05) : 601 - 608
  • [7] Influence of Recombination on Development of Mutational Resistance to Linezolid in Enterococcus faecalis JH2-2
    Boumghar-Bourtchai, Leyla
    Dhalluin, Anne
    Malbruny, Brigitte
    Galopin, Sebastien
    Leclercq, Roland
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) : 4007 - 4009
  • [8] Oxazolidinones: activity, mode of action, and mechanism of resistance
    Bozdogan, B
    Appelbaum, PC
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (02) : 113 - 119
  • [9] Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens
    Carpenter, CF
    Chambers, HF
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) : 994 - 1000
  • [10] Experience with linezolid therapy in children with Osteoarticular infections
    Chen, Chih-Jung
    Chiu, Cheng-Hsun
    Lin, Tzou-Yien
    Lee, Zhon-Liau
    Yang, Wen-E.
    Huang, Yhu-Chering
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (11) : 985 - 988